GtoPdb Ligand ID: 10659

Synonyms: NKTR-214 | NKTR214
Comment: Bempegaldesleukin (NKTR-214) is an engineered variant of human interleukin-2 [4] in which Ala1 has been removed and Cys125 is substituted by Ser. The peptide is produced in E. coli and an average of 6 lysine residues are N6 substituted with [(2,7-bis{[methylpoly(oxyethylene)]carbamoyl}-9H-fluoren-9-yl)methoxy]carbonyl (PEG-Lys). In the PEG-bound form the IL-2 is inactive, but In vivo the PEG chains are released slowly which provides a more controlled release of active IL-2 peptide [4] (the IL-2 conjugates with 1 or 2 PEG chains are the most biologically active conjugates [3]). This prodrug strategy mitigates against the severe side effects which limit maximal dosing of parental aldesleukin.
Compound class Peptide or derivative
International Nonproprietary Names
INN number INN
10593 bempegaldesleukin
NKTR-214 | NKTR214
Database Links
CAS Registry No. 1939126-74-5 (source: WHO INN record)
GtoPdb PubChem SID 404859106
Search PubMed clinical trials bempegaldesleukin
Search PubMed titles bempegaldesleukin
Search PubMed titles/abstracts bempegaldesleukin